Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AC Immune SA ( (ACIU) ) has shared an update.
On December 11, 2025, AC Immune SA announced positive interim results from its Phase 2 VacSYn trial for ACI-7104.056, an anti-alpha-synuclein immunotherapy for early Parkinson’s disease. The results suggest that the therapy could slow disease progression, with all immunogenicity targets met and no significant safety issues reported. These findings indicate potential for transforming Parkinson’s treatment and support further development, with plans to discuss a clinical development plan with regulators.
The most recent analyst rating on (ACIU) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on AC Immune SA stock, see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
AC Immune SA’s stock score is primarily impacted by its financial performance, which shows potential but is hindered by ongoing net losses and volatility. Technical analysis indicates a bearish trend with weak momentum, while valuation metrics are unfavorable due to negative earnings. The absence of earnings call insights and corporate events means these factors do not influence the score.
To see Spark’s full report on ACIU stock, click here.
More about AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company specializing in precision prevention for neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company leverages its clinically validated technology platforms, SupraAntigen® and Morphomer®, to develop a pipeline of therapeutic and diagnostic programs.
Average Trading Volume: 305,383
Technical Sentiment Signal: Hold
Current Market Cap: $251.3M
See more data about ACIU stock on TipRanks’ Stock Analysis page.